Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy.

PURPOSE The purpose of this study was to assess the prognostic value of the expression of p53 and bcl-2, the apoptotic index and the expression of topoisomerase II alpha in patients with inoperable non-small cell lung cancer (NSCLC) treated with high dose radiotherapy. PATIENTS AND METHODS A number of 161 patients with inoperable NSCLC treated with high dose radiotherapy (60 Gy) were included. Immunohistochemical analysis was used to assess the expression of nuclear p53-protein, topoisomerase II alpha and cytoplasmatic expression of bcl-2, while spontaneous apoptosis was assessed using in situ labeling. The minimal follow up period was 2 years. RESULTS Local control did not only depend on the presence of p53 expression, but also on the proportion of p53 positive cells. The most important prognostic factor was the apoptotic index. A high apoptotic index was associated with worse local control, more distant metastases and a significantly worse overall survival. No association was noted between the expression of bcl-2 and topoisomerase II alpha with any of the endpoints. CONCLUSION This study indicates that p53 expression and the apoptotic index are prognostic factors with regard to local control in patients with inoperable NSCLC treated with radiotherapy and by combining these 2 factors, a clinically relevant estimation of the local control probability can be made. The apoptotic index turned out to be the only factor significantly related to survival.

[1]  G. Gobe,et al.  Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[2]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[3]  Z. Zakeri,et al.  Cell death/apoptosis: normal, chemically induced, and teratogenic effect. , 1997, Mutation research.

[4]  C. West,et al.  A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. , 1999, International journal of radiation oncology, biology, physics.

[5]  J. Lee,et al.  Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Komaki,et al.  Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. , 1996, International journal of radiation oncology, biology, physics.

[7]  D. J. Collins,et al.  THE SPONTANEOUS OCCURRENCE OF APOPTOSIS IN SQUAMOUS CARCINOMAS OF THE UTERINE CERVIX , 1973, Pathology.

[8]  G. Sauter,et al.  NUCLEAR p53 OVEREXPRESSION IS AN INDEPENDENT PROGNOSTIC PARAMETER IN NODE‐NEGATIVE NON‐SMALL CELL LUNG CARCINOMA , 1996, The Journal of pathology.

[9]  C. Potten,et al.  Extreme sensitivity of some intestinal crypt cells to X and γ irradiation , 1977, Nature.

[10]  B. Vogelstein,et al.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms , 1994, The Journal of pathology.

[11]  S. Perkins,et al.  Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues. , 1994, Modern Pathology.

[12]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.

[13]  S. Steinberg,et al.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.

[14]  E. Wouters,et al.  The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  K. Sugimachi,et al.  p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[17]  J. Hendry,et al.  Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[19]  K. Ang,et al.  ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. , 1995, International journal of radiation oncology, biology, physics.

[20]  K. Ang,et al.  Apoptosis in irradiated murine tumors. , 1991, Radiation research.

[21]  P. Scardino,et al.  The frequency of apoptosis correlates with the prognosis of gleason grade 3 adenocarcinoma of the prostate , 1995, Cancer.

[22]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[23]  N. Osheroff.  Biochemical basis for the interactions of type I and type II topoisomerases with DNA. , 1989, Pharmacology & therapeutics.

[24]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[25]  J. Wang,et al.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[27]  K. Ang,et al.  Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. , 1993, International journal of radiation biology.

[28]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[29]  P. Lipponen,et al.  Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. , 1994, European journal of cancer.

[30]  J. Hendry,et al.  Intestinal cell radiosensitivity: a comparison for cell death assayed by apoptosis or by a loss of clonogenicity. , 1982, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[31]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[32]  J. Kerr,et al.  Deletion of cells by apoptosis during castration-induced involution of the rat prostate , 1973, Virchows Archiv. B, Cell pathology.

[33]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[34]  A. Wyllie.  The biology of cell death in tumours. , 1985, Anticancer research.

[35]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[36]  J. Holden,et al.  Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[37]  R. Slebos,et al.  Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. , 1993, Cancer research.

[38]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[39]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[40]  É. Lartigau,et al.  New trends for improving radiation sensitivity by counteracting chronic and acute hypoxia , 1994 .

[41]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[42]  C. Sarraf,et al.  Proportions of Mitotic and Apoptotic Cells In A Range of Untreated Experimental Tumours , 1988, Cell and tissue kinetics.

[43]  A. L. Woods,et al.  Immunohistochemical markers of cellular proliferation: achievements, problems and prospects , 1990, Cell and tissue kinetics.

[44]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[45]  J. Gerdes.  Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. , 1990, Seminars in cancer biology.

[46]  D. Lane,et al.  The relationship of p53 immunostaining to survival in carcinoma of the lung. , 1992, British Journal of Cancer.

[47]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.